14 results
As public budgets tighten, institutional investors are moving aggressively into neurology and outpatient diagnostics. Vanadium investigates the long-term impact on clinical independence.
Following breakthrough data from the Copenhagen summit, three major labs are pivoting their oncology pipelines toward one of the deadliest cancers.
New modelling suggests the flagship long-term workforce plan is running short.
The MHRA has signaled a stricter stance on black-box algorithms in clinical settings.
A predictable regulatory environment and a wealthy patient base are making Swiss providers a target for transatlantic capital.
The GLP-1 wave is reshaping capital allocation across the pharma landscape.
Total debt across the 42 ICBs has surpassed £1.2bn.
Even at the top of the market, independent providers are struggling to fill senior clinical roles.
A draft regulation on clinical data residency could reshape cross-border trial economics.
Cost-benefit analyses show a seven-year break-even point.
Multi-year framework agreements are unraveling.
Series A funding rounds have plummeted 34%.
Offshore production facilities face mounting logistical hurdles.
The incoming Chief Clinical Officer signals a shift toward integrated care delivery.